The Patents on Glucocorticosteroids and Selected New Therapies for the Management of Asthma in Children: Update
Iwona Stelmach, Daniela Podlecka, Makandjou-Ola Eusebio, Tomasz Grzelewski and Miroslawa Pietruczuk
Affiliation: Department of Pediatrics and Allergy, N Copernicus Hospital, 62 Pabianicka Street, 93-513, Lodz, Poland.
Keywords: Adenosine, asthma, children, glucocorticosteroids, patent, vitamin D.
Despite the continuous increase in the prevalence of asthma in many developing countries, there have been major
advances in understanding and managing this disease. The remarkable role of inflammation in asthma is well known.
Current asthma guidelines recommend the use of anti-inflammatory drugs and immunotherapy for long-term management
of asthma. The management of asthma in children is a challenge because of their inability to express warning signs and
seek medical attention in a timely manner. Unlike adults, asthmatic children must rely on their parents or caregivers for
the administration of asthma medications. The inability to carry and self-administer asthma drugs may increase the risk of
non-compliance. Glucocorticosteroids, the most important drugs for patients with asthma, are associated with an increased
level of side effects and compliance issues mostly in children. In an attempt to solve that dilemma, emphasis is being
placed on the modification of current management tactics and the introduction of other drugs. This review presents more
recent patents for childhood asthma therapies for the management of asthma in children.
Rights & PermissionsPrintExport